Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyper-CVAD versus arsenic + interferon + zidovudine for acute adult T-cell leukemia
IRCT20210703051770N1Phase 2Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Mar 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate and 3 more in adult T-cell leukemia-lymphoma (ATLL) (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Complete remission and Overall survival rate. Started Mar 2022; status: completed.
02
Drugs
cyclophosphamidevincristinedoxorubicindexamethasonemethotrexate
03
Conditions
adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on IRCT20210703051770N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210703051770N1.